Webcast ImageWebcast
AmerisourceBergen at UBS Global Healthcare Conference  (Replay)
05/20/13 at 1:30 p.m. ET

AmerisourceBergen at UBS Global Healthcare Conference
Monday, May 20, 2013 1:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
DateTitleSynopsis
04/25/13
Q2 2013 AmerisourceBergen Earnings Conference Call
 
03/19/13
AmerisourceBergen Announces Strategic, Long-Term Relationship with Walgreens and Alliance Boots - Conference Call
 
01/24/13
Q1 2013 AmerisourceBergen Earnings Conference Call
 
01/09/13
AmerisourceBergen at JPMorgan Global Healthcare Conference
 
12/12/12
AmerisourceBergen Investor Day
 
11/01/12
Q4 2012 AmerisourceBergen Earnings Conference Call
 

Certain of the statements contained in these webcasts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. Among the factors that could cause actual results to differ materially from those projected, anticipated or implied are the following: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale and purchase of pharmaceutical products or any related litigation, including shareholder derivative lawsuits; changes in federal and state legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical products we distribute, including certain anemia products; price inflat